Vera Ehrenstein

Vera Ehrenstein

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Vera Ehrenstein

Department of Clinical Epidemiology Aarhus University and Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
MSMorten Schmidt
Morten Schmidt
SSSigrun Alba Johannesdottir Schmidt
Sigrun Alba Johannesdottir Schmidt
JSJakob Lynge Sandegaard
Jakob Lynge Sandegaard
VEVera Ehrenstein
Vera Ehrenstein
LPLars Pedersen
Lars Pedersen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
Background: The Danish National Patient Registry (DNPR) is one of the world's oldest nationwide hospital registries and is used extensively for research. Many studies have validated algorithms for identifying health events in the DNPR, but the reports are fragmented and no overview exists. Objectives: To review the content, data quality, and research potential of the DNPR. Methods: We examined the setting, history, aims, content, and classification systems of the DNPR. We searched PubMed and the Danish Medical Journal to create a bibliography of validation studies. We included also studies that were referenced in retrieved papers or known to us beforehand. Methodological considerations related to DNPR data were reviewed. Results: During 1977–2012, the DNPR registered 8,085,603 persons, accounting for 7,268,857 inpatient, 5,953,405 outpatient, and 5,097,300 emergency department contacts. The DNPR provides nationwide longitudinal registration of detailed administrative and clinical data. It has recorded information on all patients discharged from Danish nonpsychiatric hospitals since 1977 and on psychiatric inpatients and emergency department and outpatient specialty clinic contacts since 1995. For each patient contact, one primary and optional secondary diagnoses are recorded according to the International Classification of Diseases. The DNPR provides a data source to identify diseases, examinations, certain in-hospital medical treatments, and surgical procedures. Long-term temporal trends in hospitalization and treatment rates can be studied. The positive predictive values of diseases and treatments vary widely (<15%–100%). The DNPR data are linkable at the patient level with data from other Danish administrative registries, clinical registries, randomized controlled trials, population surveys, and epidemiologic field studies – enabling researchers to reconstruct individual life and health trajectories for an entire population. Conclusion: The DNPR is a valuable tool for epidemiological research. However, both its strengths and limitations must be considered when interpreting research results, and continuous validation of its clinical data is essential.

1 July 2019 in Clinical Epidemiology
Verified
Journal Article
Open access
MSMorten Schmidt
Morten Schmidt
SSSigrun Alba Johannesdottir Schmidt
Sigrun Alba Johannesdottir Schmidt
KAKasper Adelborg
Kasper Adelborg
JSJens Sundbøll
Jens Sundbøll
KLKristina Laugesen
Kristina Laugesen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
Denmark has a large network of population-based medical databases, which routinely collect high-quality data as a by-product of health care provision. The Danish medical databases include administrative, health, and clinical quality databases. Understanding the full research potential of these data sources requires insight into the underlying health care system. This review describes key elements of the Danish health care system from planning and delivery to record generation. First, it presents the history of the health care system, its overall organization and financing. Second, it details delivery of primary, hospital, psychiatric, and elderly care. Third, the path from a health care contact to a database record is followed. Finally, an overview of the available data sources is presented. This review discusses the data quality of each type of medical database and describes the relative technical ease and cost-effectiveness of exact individual-level linkage among them. It is shown, from an epidemiological point of view, how Denmark's population represents an open dynamic cohort with complete long-term follow-up, censored only at emigration or death. It is concluded that Denmark's constellation of universal health care, long-standing routine registration of most health and life events, and the possibility of exact individual-level data linkage provides unlimited possibilities for epidemiological research.

14 November 2018 in BMJ
Verified
Journal Article
Open access
PDF file
SLSinéad M Langan
Sinéad M Langan
SSSigrún Aj Schmidt
Sigrún Aj Schmidt
KWKevin Wing
Kevin Wing
VEVera Ehrenstein
Vera Ehrenstein
SNStuart G. Gordon Nicholls
Stuart G. Gordon Nicholls
EBEric I Benchimol
Eric I Benchimol
In pharmacoepidemiology, routinely collected data from electronic health records (including primary care databases, registries, and administrative healthcare claims) are a resource for research evaluating the real world effectiveness and safety of medicines. Currently available guidelines for the reporting of research using non-randomised, routinely collected data—specifically the REporting of studies Conducted using Observational Routinely collected health Data (RECORD) and the Strengthening the Reporting of OBservational studies in Epidemiology (STROBE) statements—do not capture the complexity of pharmacoepidemiological research. We have therefore extended the RECORD statement to include reporting guidelines specific to pharmacoepidemiological research (RECORD-PE). This article includes the RECORD-PE checklist (also available on www.record-statement.org) and explains each checklist item with examples of good reporting. We anticipate that increasing use of the RECORD-PE guidelines by researchers and endorsement and adherence by journal editors will improve the standards of reporting of pharmacoepidemiological research undertaken using routinely collected data. This improved transparency will benefit the research community, patient care, and ultimately improve public health.

13 May 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
SJSigrun A. Johannesdottir
Sigrun A. Johannesdottir
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
ODOlaf M. Dekkers
Olaf M. Dekkers
SCSuzanne C. Cannegieter
Suzanne C. Cannegieter
JJJens Otto L. Jørgensen
Jens Otto L. Jørgensen
HSHenrik Toft Sørensen
Henrik Toft Sørensen
Venous thromboembolism (VTE) is a common disease affecting more than 1 per 1000 persons each year in Western populations.1-3 Typically, it presents as deep venous thrombosis (DVT) of the legs and can result in pulmonary embolism (PE), a potentially fatal complication.1-3

1 June 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
ODOlaf M. Dekkers
Olaf M. Dekkers
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
JJJens Otto L. Jørgensen
Jens Otto L. Jørgensen
SCSuzanne C. Cannegieter
Suzanne C. Cannegieter
VEVera Ehrenstein
Vera Ehrenstein
HSHenrik Toft Sørensen
Henrik Toft Sørensen
Cushing's syndrome (CS) is associated with hypercoagulability, insulin resistance, hypertension, bone loss, and immunosuppression. To date, no adequately large cohort study has been performed to assess the multisystem effects of CS. We aimed to examine the risks for mortality, cardiovascular disease, fractures, peptic ulcers, and infections in CS patients before and after treatment. Population-based cohort study. Source population was the entire population of Denmark (1980 to 2010). Data were obtained from the Danish National Registry of Patients and the Danish Civil Registration System. Benign CS of adrenal or pituitary origin and a matched population comparison cohort were included. We used Cox regression, and computed hazard ratios (HR) with 95% confidence intervals (95% CI). Morbidity was investigated in the 3 years before diagnosis; morbidity and mortality were assessed during complete follow-up after diagnosis and treatment. Included were 343 CS patients and 34 300 controls. Mortality was twice as high in CS patients (HR 2.3, 95%CI 1.8-2.9) compared with controls. Patients with CS were at increased risk for venous thromboembolism (HR 2.6, 95%CI 1.5-4.7), myocardial infarction (HR 3.7, 95%CI 2.4-5.5), stroke (HR 2.0, 95%CI 1.3-3.2), peptic ulcers (HR 2.0, 95%CI 1.1-3.6), fractures (HR 1.4, 95%CI 1.0-1.9), and infections (HR 4.9, 95%CI 3.7-6.4). This increased multimorbidity risk was present before diagnosis. Mortality and risk of myocardial infarction remained elevated during long-term follow-up. Mortality and risks for acute myocardial infarction, venous thromboembolism, stroke, and infections were similarly increased in adrenal and pituitary CS. Despite the apparently benign character of the disease, CS is associated with clearly increased mortality and multisystem morbidity, even before diagnosis and treatment.

1 November 2012 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
SJSigrun Alba Johannesdottir
Sigrun Alba Johannesdottir
EHErzsébet Horváth-Puhó
Erzsébet Horváth-Puhó
VEVera Ehrenstein
Vera Ehrenstein
MSMorten Schmidt
Morten Schmidt
LPLars Pedersen
Lars Pedersen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
The Danish health care system provides partial reimbursement of most prescription medications in Denmark. The dispensation of prescription medications is registered in administrative databases. Each time a prescription is redeemed at a pharmacy, an electronic record is generated with information related to the user, prescriber, the pharmacy, and the dispensed drug. The National Health Service gathers this information for administration of the drug reimbursement plan. Recently, this information became the basis for the establishment of a new research database, the Danish National Database of Reimbursed Prescriptions (DNDRP). In this paper, we review the content, coverage, quality, linkage, access, and research possibilities of this new database. The database encompasses the reimbursement records of all reimbursed drugs sold in community pharmacies and hospital-based outpatient pharmacies in Denmark since 2004. On average, approximately 3.5 million users are recorded in the database each year. During the coverage period, the number of annual prescription redemptions increased by 15%. Most dispensed prescriptions are in the categories “alimentary tract and metabolism”, “cardiovascular system”, “nervous system”, and “respiratory system”. Individuals are identified by the unique central personal registration (CPR) number assigned to all persons born in or immigrating to Denmark. The new database fully complies with Denmark’s Act on Processing of Personal Data, while avoiding additional restrictions imposed on data use at the Danish National Prescription Registry, administered by Statistics Denmark. Most importantly, CPR numbers are reversibly encrypted, which allows re-identification of drug users; furthermore, the data access is possible outside the servers of Statistics Denmark. These features open additional opportunities for international collaboration, validation studies, studies on adverse drug effects requiring review of medical records, studies involving contact to general practitioners, and linkage of prescription data to other clinical and research databases. The DNDRP thus is a valuable data source for pharmacoepidemiological research.